October Term 2012 · Docket 12-416

Do patent settlement payments violate antitrust law?

The FTC argues these payments harm consumers. Actavis claims they resolve patent disputes.

Official caption
FTC v. Actavis, Inc.
Latest argument session
Latest official Court activity
Latest verified event
Argued
Sources analyzed through
Official Transcript

Verified source milestones

  1. — An official oral-argument transcript was verified.
  2. — An official oral-argument transcript was verified.

The arguments, in order

This case may have been argued more than once. Each entry below uses that session's official transcript. Later arguments do not erase earlier ones.

  1. Argument 1 ·

    What happened at the argument

    Mr. Stewart argued payments for non-competition violate antitrust law.

    Justice Kennedy questioned if the test ignores patent strength.

    Justice Ginsburg asked if the government changed its position.

    Read the official transcript for this argument · Official argument details

    Sources used for this argument breakdown

A citizen's guide to the whole case

What this case is about

This case tests whether brand-name drug makers can pay generic rivals to delay market entry. The FTC says this practice suppresses competition. Actavis argues it settles valid patent disputes.

Official sources for this section

How the case got here

The Supreme Court heard oral argument in this case on March 25, 2013.

Official sources for this section

What each side wants

The FTC wants the Court to strike down these payment agreements.

Actavis wants the Court to uphold the settlement as lawful.

Official sources for this section

What each side says

The FTC argues payments for non-competition are antitrust violations.

Actavis argues the payments resolve genuine patent uncertainty.

Official sources for this section

What the justices asked

Justice Scalia asked if Hatch-Waxman amendments caused this issue.

Justice Scalia questioned why payments differ from market division.

Official sources for this section

Why it matters

This dispute affects drug prices and consumer access. It defines the limits of patent settlements. The outcome shapes future antitrust enforcement.

Official sources for this section

What happens next

This article currently covers the argument record. Use the official docket link for later case activity.

Official sources for this section

Official Court provenance

Official docket and case history · Official Supreme Court oral-argument detail page

Title and summary sources

Revision history

  1. Revision 1 · Official Transcript ·

    Correction: Rewritten to the concise citizen-facing editorial standard.

  2. Revision 2 · Official Transcript ·

    Correction: Migrated to the dated official Court activity contract without model use.

Download this sanitized case as JSON